Device Trial Radar · NCT03111420
Study of AggreGuide A-100 (ADP) Assay
Last checked: Nov 20, 2026Latest source record: Feb 21, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
280
Actual
Start
Jan 9, 2017
Primary completion
Jun 2018
Study completion Jun 2018
Sponsor
- Lead sponsor
- Aggredyne, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Apr 12, 2017
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Diagnostic
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 22 years, up to 74 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Study to evaluate the performance of the AggreGuide A-100 ADP assay for detection of platelet dysfunction caused by P2Y12 inhibitor antiplatelet therapy.
Conditions
- Risk Factor, Cardiovascular
- Platelet Dysfunction Due to Drugs
Interventions
P2Y12 inhibitorDrug
Administration of P2Y12 inhibitor antiplatelet therapy
Platelet function testDevice
Blood is drawn for testing of platelet aggregation activity
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Platelet Activity Index (PAI)Time frame: Baseline, day 1, day 7
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.